ABI
MYGN icon

Adamant Biomedical Investments’s Myriad Genetics MYGN Stock Holding History

Adamant Biomedical Investments’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$817K Hold
24,000
– – 0.2% 85
2014
Q3 		$926K Buy
+24,000
New +$895K 0.23% 78

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 16.21% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Adamant Biomedical Investments's MYGN Position: Q4 2014 in Review

Adamant Biomedical Investments held its Myriad Genetics (MYGN) position steady in Q4 2014 at 24,000 shares worth $817K. The position accounts for 0.2% of the portfolio, ranked #85.

Adamant Biomedical Investments first reported a position in MYGN in Q3 2014 and has held it in 2 quarters since. The position peaked at $926K in Q3 2014. 273 funds tracked by Wall St. Rank hold MYGN as of Q4 2014.

  • Adamant Biomedical Investments held 24,000 shares of Myriad Genetics worth $817K as of Q4 2014.
  • Adamant Biomedical Investments left its Myriad Genetics share count unchanged in Q4 2014.
  • Myriad Genetics made up 0.2% of Adamant Biomedical Investments's portfolio in Q4 2014, its #85 holding.
  • Adamant Biomedical Investments first reported a position in Myriad Genetics in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's Myriad Genetics position peaked at $926K in Q3 2014.
  • 273 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.